clindamycin phosphate
clindamycin phosphate is listed in the FDA National Drug Code directory with 58 NDC codes, marketed under brand names including XACIATO, Cleocin Phosphate, clindamycin phosphate. Available dosage forms: gel, injection, solution, aerosol, foam, lotion, cream.
Drug details
- Generic Name
- clindamycin phosphate
- Brand Names
- XACIATO, Cleocin Phosphate, clindamycin phosphate, Clindamycin Phosphate, CLEOCIN PHOSPHATE, Cleocin, Clindesse, Clindacin P, Cleocin T, CLINDAMYCIN PHOSPHATE, Clindacin, Clindacin ETZ
- Application Number
- NDA215650
- Sponsor
- Organon LLC
- NDC Codes
- 58
- Dosage Forms
- GEL, INJECTION, SOLUTION, AEROSOL, FOAM, LOTION, CREAM, SOLUTION, SUPPOSITORY, SWAB
- Routes
- VAGINAL, INTRAMUSCULAR, INTRAVENOUS, TOPICAL
- Active Ingredients
- CLINDAMYCIN PHOSPHATE
Indications and Usage
INDICATIONS AND USAGE Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES .) NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, eg, Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans, and Herpes simplex virus should be ruled out.
Warnings
WARNINGS Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild to life-threatening. Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of orally and parenterally administered clindamycin, as well as with topical (dermal and vaginal) formulations of clindamycin. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of clindamycin, even when administered by the vaginal route, because approximately 5% of the clindamycin dose is systemically absorbed from the vagina. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridioides difficile is a primary cause of "antibiotic-associated" colitis. After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against Clostridioides difficile colitis. Onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.